Multifunctional Enveloped Nanodevices (MENDs)

Advances in Genetics

Volumn 88, Issue , 2014, Pages 139-204

  Sato, Yusuke ^a   Nakamura, Takashi ^a   Yamada, Yuma ^a   Akita, Hidetaka ^a   Harashima, Hideyoshi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

A multifunctional envelope type nanodevice (MEND); Intracellular trafficking; KALA; MITO Poter; Mitochondrial targeting; Nuclear targeting; Octaarginine (R8); PH sensitive cationic lipid; Proton activated lipid like material (PALM); YSK

Indexed keywords

DNA BINDING PROTEIN; IMMUNOLOGICAL ADJUVANT; KALA AMPHIPATHIC PEPTIDE; LIPID; LIPOSOME; NANOPARTICLE; NUCLEIC ACID; OCTAARGININE; OLIGODEOXYRIBONUCLEOTIDE; OLIGOPEPTIDE; PEPTIDE; PEPTIDE NUCLEIC ACID; SMALL INTERFERING RNA;

CHEMISTRY; DEVICES; DRUG DELIVERY SYSTEM; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; HUMAN; MEMBRANE FUSION; MITOCHONDRION; NANOMEDICINE; PHARMACOLOGY; PROCEDURES;

ADJUVANTS, IMMUNOLOGIC; DNA-BINDING PROTEINS; DRUG DELIVERY SYSTEMS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; LIPIDS; LIPOSOMES; MEMBRANE FUSION; MITOCHONDRIA; NANOMEDICINE; NANOPARTICLES; NUCLEIC ACIDS; OLIGODEOXYRIBONUCLEOTIDES; OLIGOPEPTIDES; PEPTIDE NUCLEIC ACIDS; PEPTIDES; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84909998203     PISSN: 00652660     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-800148-6.00006-7     Document Type: Chapter

References (228)

1. Abrams M.T., Koser M.L., Seitzer J., Williams S.C., DiPietro M.A., Wang W., et al. Evaluation of efficacy, biodistribution, and inflammation for a potent siRNA nanoparticle: effect of dexamethasone co-treatment. Molecular Therapy 2010, 18(1):171-180.
2. Adami R.C., Seth S., Harvie P., Johns R., Fam R., Fosnaugh K., et al. An amino acid-based amphoteric liposomal delivery system for systemic administration of siRNA. Molecular Therapy 2011, 19(6):1141-1151.
3. Akinc A., Querbes W., De S., Qin J., Frank-Kamenetsky M., Jayaprakash K.N., et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Molecular Therapy 2010, 18(7):1357-1364.
4. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124(4):783-801.
5. Akita H., Enoto K., Masuda T., Mizuguchi H., Tani T., Harashima H. Particle tracking of intracellular trafficking of octaarginine-modified liposomes: a comparative study with adenovirus. Molecular Therapy 2010, 18(5):955-964.
6. Akita H., Hatakeyama H., Khalil I., Yamada Y., Harashima H. Delivery of nucleic acids and gene delivery. Comprehensive biomaterials 2011, Vol. 4:411-444. P. Ducheyne, K.E. Healy, D.W. Hutmacher, D.W. Grainger, C.J. Kirkpatrick (Eds.).
7. Akita H., Ishiba R., Hatakeyama H., Tanaka H., Sato Y., Tange K., et al. A neutral envelope-type nanoparticle containing pH-responsive and SS-cleavable lipid-like material as a carrier for plasmid DNA. Advanced Healthcare Materials 2013, 2(8):1120-1125.
8. Akita H., Ishii S., Miura N., Shaheen S.M., Hayashi Y., Nakamura T., et al. A DNA microarray-based analysis of immune-stimulatory and transcriptional responses of dendritic cells to KALA-modified nanoparticles. Biomaterials 2013, 34(35):8979-8990.
9. Akita H., Ito R., Kamiya H., Kogure K., Harashima H. Cell cycle dependent transcription, a determinant factor of heterogeneity in cationic lipid-mediated transgene expression. Journal of General Medicine 2007, 9(3):197-207.
10. Akita H., Ito R., Khalil I.A., Futaki S., Harashima H. Quantitative three-dimensional analysis of the intracellular trafficking of plasmid DNA transfected by a nonviral gene delivery system using confocal laser scanning microscopy. Molecular Therapy 2004, 9(3):443-451.
11. Akita H., Kogure K., Moriguchi R., Nakamura Y., Higashi T., Nakamura T., et al. Nanoparticles for exvivo siRNA delivery to dendritic cells for cancer vaccines: programmed endosomal escape and dissociation. Journal of Controlled Release 2010, 143(3):311-317.
12. Akita H., Kudo A., Minoura A., Yamaguti M., Khalil I.A., Moriguchi R., et al. Multi-layered nanoparticles for penetrating the endosome and nuclear membrane via a step-wise membrane fusion process. Biomaterials 2009, 30(15):2940-2949.
13. Akita H., Masuda T., Nishio T., Niikura K., Ijiro K., Harashima H. Improving invivo hepatic transfection activity by controlling intracellular trafficking: the function of GALA and maltotriose. Molecular Pharmaceutics 2011, 8(4):1436-1442.
14. Akita H., Umetsu Y., Kurihara D., Harashima H. Dual imaging of mRNA and protein production: an investigation of the mechanism of heterogeneity in cationic lipid-mediated transgene expression. International Journal for Pharmaceutics 2011, 415(1-2):218-220.
15. Alabi C.A., Love K.T., Sahay G., Yin H., Luly K.M., Langer R., et al. Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery. Proceedings of the National Academy of Sciences of the United States of America 2013, 110(32):12881-12886.
16. Barber G.N. Innate immune DNA sensing pathways: STING, AIMII and the regulation of interferon production and inflammatory responses. Current Opinion in Immunology 2011, 23(1):10-20.
17. Barral D.C., Brenner M.B. CD1 antigen presentation: how it works. Nature Reviews Immunology 2007, 7(12):929-941.
18. Belting M. Heparan sulfate proteoglycan as a plasma membrane carrier. Trends in Biochemical Sciences 2003, 28(3):145-151.
19. Bohnert M., Pfanner N., van der Laan M. A dynamic machinery for import of mitochondrial precursor proteins. FEBS Letters 2007, 581(15):2802-2810.
20. Bonamassa B., Hai L., Liu D. Hydrodynamic gene delivery and its applications in pharmaceutical research. Pharmaceutical Research 2011, 28(4):694-701.
21. Budhu A.S., Noy N. Direct channeling of retinoic acid between cellular retinoic acid-binding protein II and retinoic acid receptor sensitizes mammary carcinoma cells to retinoic acid-induced growth arrest. Molecular and Cellular Biology 2002, 22(8):2632-2641.
22. Cabral H., Matsumoto Y., Mizuno K., Chen Q., Murakami M., Kimura M., et al. Accumulation of sub-100nm polymeric micelles in poorly permeable tumours depends on size. Nature Nanotechnology 2011, 6(12):815-823.
23. Chauhan V.P., Stylianopoulos T., Martin J.D., Popović Z., Chen O., Kamoun W.S., et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nature Nanotechnology 2012, 7(6):383-388.
24. Chen Z., Felsheim R., Wong P., Augustin L.B., Metz R., Kren B.T., et al. Mitochondria isolated from liver contain the essential factors required for RNA/DNA oligonucleotide-targeted gene repair. Biochemical and Biophysical Research Communications 2001, 285(2):188-194.
25. Chinnery P.F., Turnbull D.M. Mitochondrial DNA mutations in the pathogenesis of human disease. Molecular Medicine Today 2000, 6(11):425-432.
26. Cohen R.N., van der Aa M.A., Macaraeg N., Lee A.P., Szoka F.C. Quantification of plasmid DNA copies in the nucleus after lipoplex and polyplex transfection. Journal of Controlled Release 2009, 135(2):166-174.
27. D'Souza G.G., Boddapati S.V., Weissig V. Mitochondrial leader sequence-plasmid DNA conjugates delivered into mammalian cells by DQAsomes co-localize with mitochondria. Mitochondrion 2005, 5(5):352-358.
28. D'Souza G.G., Rammohan R., Cheng S.M., Torchilin V.P., Weissig V. DQAsome-mediated delivery of plasmid DNA toward mitochondria in living cells. Journal of Controlled Release 2003, 92(1-2):189-197.
29. Davis M.E., Zuckerman J.E., Choi C.H., Seligson D., Tolcher A., Alabi C.A., et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464(7291):1067-1070.
30. Davtyan H., Hovakimyan A., Zagorski K., Davtyan A., Petrushina I., Agdashian D., et al. BTX AgilePulseTM system is an effective electroporation device for intramuscular and intradermal delivery of DNA vaccine. Current Gene Therapy 2014, 14:190-199.
31. Del Gaizo V., MacKenzie J.A., Payne R.M. Targeting proteins to mitochondria using TAT. Molecular Genetics and Metabolism 2003, 80(1-2):170-180.
32. Del Gaizo V., Payne R.M. A novel TAT-mitochondrial signal sequence fusion protein is processed, stays in mitochondria, and crosses the placenta. Molecular Therapy 2003, 7(6):720-730.
33. Derossi D., Chassaing G., Prochiantz A. Trojan peptides: the penetratin system for intracellular delivery. Trends in Cell Biology 1998, 8(2):84-87.
34. Desmet C.J., Ishii K.J. Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination. Nature Reviews in Immunology 2012, 12(7):479-491.
35. Dietz G.P., Bahr M. Delivery of bioactive molecules into the cell: the Trojan horse approach. Molecular and Cellular Neuroscience 2004, 27(2):85-131.
36. Dietz A.B., Vuk-Pavlovic S. High efficiency adenovirus-mediated gene transfer to human dendritic cells. Blood 1998, 91(2):392-398.
37. DiMauro S. Mitochondrial myopathies. Current Opinion in Rheumatology 2006, 18(6):636-641.
38. Domashenko A., Gupta S., Cotsarelis G. Efficient delivery of transgenes to human hair follicle progenitor cells using topical lipoplex. Nature Biotechnology 2000, 18(4):420-423.
39. Duchene A.M., Pujol C., Marechal-Drouard L. Import of tRNAs and aminoacyl-tRNA synthetases into mitochondria. Current Genetics 2009, 55(1):1-18.
40. Eikenes L., Tari M., Tufto I., Bruland O.S., de Lange Davies C. Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx) in human osteosarcoma xenografts. British Journal of Cancer 2005, 93(1):81-88.
41. El-Sayed A., Khalil I.A., Kogure K., Futaki S., Harashima H. Octaarginine- and octalysine-modified nanoparticles have different modes of endosomal escape. Journal of Biological Chemistry 2008, 283(34):23450-23461.
42. Endo T.A., Masuhara M., Yokouchi M., Suzuki R., Sakamoto H., Mitsui K., et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 1997, 387(6636):921-924.
43. Endo T., Nakayama Y., Nakai M. Avidin fusion protein as a tool to generate a stable translocation intermediate spanning the mitochondrial membranes. Journal of Biochemistry 1995, 118(4):753-759.
44. Esaki M., Kanamori T., Nishikawa S., Endo T. Two distinct mechanisms drive protein translocation across the mitochondrial outer membrane in the late step of the cytochrome b(2) import pathway. Proceedings of the National Academy of Sciences of the United States of America 1999, 96(21):11770-11775.
45. Flierl A., Jackson C., Cottrell B., Murdock D., Seibel P., Wallace D.C. Targeted delivery of DNA to the mitochondrial compartment via import sequence-conjugated peptide nucleic acid. Molecular Therapy 2003, 7(4):550-557.
46. Fujimori K., Covell D.G., Fletcher J.E., Weinstein J.N. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. Journal of Nuclear Medicine 1990, 31(7):1191-1198.
47. Fujiwara K., Nagoshi S., Ohno A., Hirata K., Ohta Y., Mochida S., et al. Stimulation of liver growth by exogenous human hepatocyte growth factor in normal and partially hepatectomized rats. Hepatology 1993, 18(6):1443-1449.
48. Fumoto S., Kawakami S., Ito Y., Shigeta K., Yamashita F., Hashida M. Enhanced hepatocyte-selective invivo gene expression by stabilized galactosylated liposome/plasmid DNA complex using sodium chloride for complex formation. Molecular Therapy 2004, 10(4):719-729.
49. Futaki S., Niwa M., Nakase I., Tadokoro A., Zhang Y., Nagaoka M., et al. Arginine carrier peptide bearing Ni(II) chelator to promote cellular uptake of histidine-tagged proteins. Bioconjugate Chemistry 2004, 15(3):475-481.
50. Futaki S., Ohashi W., Suzuki T., Niwa M., Tanaka S., Ueda K., et al. Stearylated arginine-rich peptides: a new class of transfection systems. Bioconjugate Chemistry 2001, 12(6):1005-1011.
51. Futaki S., Suzuki T., Ohashi W., Yagami T., Tanaka S., Ueda K., et al. Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. Journal of Biological Chemistry 2001, 276(8):5836-5840.
52. Gao J., Liu W., Xia Y., Li W., Sun J., Chen H., et al. The promotion of siRNA delivery to breast cancer overexpressing epidermal growth factor receptor through anti-EGFR antibody conjugation by immunoliposomes. Biomaterials 2011, 32(13):3459-3470.
53. Goto Y., Nonaka I., Horai S. A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature 1990, 348(6302):651-653.
54. Gruhler A., Ono H., Guiard B., Neupert W., Stuart R.A. A novel intermediate on the import pathway of cytochrome b2 into mitochondria: evidence for conservative sorting. Embo Journal 1995, 14(7):1349-1359.
55. Gupta B., Levchenko T.S., Torchilin V.P. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Advanced Drug Delivery Reviews 2005, 57(4):637-651.
56. Hacein-Bey-Abina S., von Kalle C., Schmidt M., Le Deist F., Wulffraat N., McIntyre E., et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. The New England Journal of Medicine 2003, 348(3):255-256.
57. Hacein-Bey-Abina S., Von Kalle C., Schmidt M., McCormack M.P., Wulffraat N., Leboulch P., et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003, 302(5644):415-419.
58. Hama S., Akita H., Iida S., Mizuguchi H., Harashima H. Quantitative and mechanism-based investigation of post-nuclear delivery events between adenovirus and lipoplex. Nucleic Acids Research 2007, 35(5):1533-1543.
59. Hama S., Akita H., Ito R., Mizuguchi H., Hayakawa T., Harashima H. Quantitative comparison of intracellular trafficking and nuclear transcription between adenoviral and lipoplex systems. Molecular Therapy 2006, 13(4):786-794.
60. Hatakeyama H., Akita H., Harashima H. The polyethyleneglycol dilemma: advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumors. Biological and Pharmaceutical Bulletin 2013, 36(6):892-899.
61. Hatakeyama H., Murata M., Sato Y., Takahashi M., Minakawa N., Matsuda A., et al. The systemic administration of an anti-miRNA oligonucleotide encapsulated pH-sensitive liposome results in reduced level of hepatic microRNA-122 in mice. Journal of Controlled Release 2014, 173:43-50.
62. Hattori K., Nishikawa M., Watcharanurak K., Ikoma A., Kabashima K., Toyota H., et al. Sustained exogenous expression of therapeutic levels of IFN-gamma ameliorates atopic dermatitis in NC/Nga mice via Th1 polarization. Journal of Immunology 2010, 184(5):2729-2735.
63. Hayashi Y., Mizuno R., Ikramy K.A., Akita H., Harashima H. Pretreatment of hepatocyte growth factor gene transfer mediated by octaarginine peptide-modified nanoparticles ameliorates LPS/D-galactosamine-induced hepatitis. Nucleic Acid Therapeutics 2012, 22(5):360-363.
64. Hayashi Y., Suemitsu E., Kajimoto K., Sato Y., Akhter A., Sakurai Y., et al. Hepatic monoacylglycerol O-acyltransferase 1 as a promising therapeutic target for steatosis, obesity, and type 2 diabetes. Molecular Therapeutics - Nucleic Acids 2014, 3:e154.
65. Herweijer H., Wolff J.A. Gene therapy progress and prospects: hydrodynamic gene delivery. Gene Therapy 2007, 14(2):99-107.
66. Hobbs S.K., Monsky W.L., Yuan F., Roberts W.G., Griffith L., Torchilin V.P., et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proceedings of the National Academy of Sciences of the United States of America 1998, 95(8):4607-4612.
67. Hodges B.L., Taylor K.M., Joseph M.F., Bourgeois S.A., Scheule R.K. Long-term transgene expression from plasmid DNA gene therapy vectors is negatively affected by CpG dinucleotides. Molecular Therapy 2004, 10(2):269-278.
68. Holt I.J., Harding A.E., Petty R.K., Morgan-Hughes J.A. A new mitochondrial disease associated with mitochondrial DNA heteroplasmy. The American Journal of Human Genetics 1990, 46(3):428-433.
69. Hu-Lieskovan S., Heidel J.D., Bartlett D.W., Davis M.E., Triche T.J. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Research 2005, 65(19):8984-8992.
70. Huo S., Ma H., Huang K., Liu J., Wei T., Jin S., et al. Superior penetration and retention behavior of 50 nm gold nanoparticles in tumors. Cancer Research 2013, 73(1):319-330.
71. Hyde S.C., Pringle I.A., Abdullah S., Lawton A.E., Davies L.A., Varathalingam A., et al. CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression. National Biotechnology 2008, 26(5):549-551.
72. Ishii K.J., Kawagoe T., Koyama S., Matsui K., Kumar H., Kawai T., et al. TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature 2008, 451(7179):725-729.
73. Ishikawa H., Barber G.N. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 2008, 455(7213):674-678.
74. Ishikawa H., Ma Z., Barber G.N. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 2009, 461(7265):788-792.
75. Ishiki Y., Ohnishi H., Muto Y., Matsumoto K., Nakamura T. Direct evidence that hepatocyte growth factor is a hepatotrophic factor for liver regeneration and has a potent antihepatitis effect invivo. Hepatology 1992, 16(5):1227-1235.
76. Iwaoka S., Nakamura T., Takano S., Tsuchiya S., Aramaki Y. Cationic liposomes induce apoptosis through p38 MAP kinase-caspase-8-Bid pathway in macrophage-like RAW264.7 cells. Journal of Leukocyte Biology 2006, 79(1):184-191.
77. Iyer S., Thomas R.R., Portell F.R., Dunham L.D., Quigley C.K., Bennett J.P. Recombinant mitochondrial transcription factor A with N-terminal mitochondrial transduction domain increases respiration and mitochondrial gene expression. Mitochondrion 2009, 9(3):196-203.
78. Jacobs F., Wisse E., De Geest B. The role of liver sinusoidal cells in hepatocyte-directed gene transfer. American Journal of Pathology 2010, 176(1):14-21.
79. Jain R.K., Stylianopoulos T. Delivering nanomedicine to solid tumors. Nature Reviews Clinical Oncology 2010, 7(11):653-664.
80. Jayaraman M., Ansell S.M., Mui B.L., Tam Y.K., Chen J., Du X., et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing invivo. Angewandte Chemie International Edition in English 2012, 51(34):8529-8533.
81. Joffre O.P., Segura E., Savina A., Amigorena S. Cross-presentation by dendritic cells. Nature Reviews Immunology 2012, 12(8):557-569.
82. Judge A.D., Robbins M., Tavakoli I., Levi J., Hu L., Fronda A., et al. Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. Journal of Clinical Investigation 2009, 119(3):661-673.
83. Juweid M., Neumann R., Paik C., Perez-Bacete M.J., Sato J., van Osdol W., et al. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Research 1992, 52(19):5144-5153.
84. Kagawa Y., Inoki Y., Endo H. Gene therapy by mitochondrial transfer. Advanced Drug Delivery Reviews 2001, 49(1-2):107-119.
85. Kajimoto K., Sato Y., Nakamura T., Yamada Y., Harashima H. Multifunctional envelope-type nano device for controlled intracellular trafficking and selective targeting invivo. Journal of Controlled Release 2014, 190:593-606.
86. Kakudo T., Chaki S., Futaki S., Nakase I., Akaji K., Kawakami T., et al. Transferrin-modified liposomes equipped with a pH-sensitive fusogenic peptide: an artificial viral-like delivery system. Biochemistry 2004, 43(19):5618-5628.
87. Kawakami S., Ito Y., Charoensit P., Yamashita F., Hashida M. Evaluation of proinflammatory cytokine production induced by linear and branched polyethylenimine/plasmid DNA complexes in mice. Journal of Pharmacology and Experimental Therapeutics 2006, 317(3):1382-1390.
88. Kawamura E., Yamada Y., Yasuzaki Y., Hyodo M., Harashima H. Intracellular observation of nanocarriers modified with a mitochondrial targeting signal peptide. Journal of Bioscience and Bioengineering 2013, 116(5):634-637.
89. Keeney P.M., Quigley C.K., Dunham L.D., Papageorge C.M., Iyer S., Thomas R.R., et al. Mitochondrial gene therapy augments mitochondrial physiology in a Parkinson's disease cell model. Human Gene Therapy 2009, 20(8):897-907.
90. Khalil I.A., Hayashi Y., Mizuno R., Harashima H. Octaarginine- and pH sensitive fusogenic peptide-modified nanoparticles for liver gene delivery. Journal of Controlled Release 2011, 156(3):374-380.
91. Khalil I.A., Kogure K., Akita H., Harashima H. Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery. Pharmacological Reviews 2006, 58(1):32-45.
92. Khalil I.A., Kogure K., Futaki S., Hama S., Akita H., Ueno M., et al. Octaarginine-modified multifunctional envelope-type nanoparticles for gene delivery. Gene Therapy 2007, 14(8):682-689.
93. Khalil I.A., Kogure K., Futaki S., Harashima H. High density of octaarginine stimulates macropinocytosis leading to efficient intracellular trafficking for gene expression. Journal of Biological Chemistry 2006, 281(6):3544-3551.
94. Khalil I.A., Kogure K., Futaki S., Harashima H. Octaarginine-modified liposomes: enhanced cellular uptake and controlled intracellular trafficking. International Journal of Pharmaceutics 2008, 354(1-2):39-48.
95. Kobielak K., Pasolli H.A., Alonso L., Polak L., Fuchs E. Defining BMP functions in the hair follicle by conditional ablation of BMP receptor IA. Journal of Cell Biology 2003, 163(3):609-623.
96. Koga Y., Akita Y., Nishioka J., Yatsuga S., Povalko N., Katayama K., et al. MELAS and l-arginine therapy. Mitochondrion 2007, 7(1-2):133-139.
97. Kogure K., Akita H., Harashima H. Multifunctional envelope-type nano device for non-viral gene delivery: concept and application of programmed packaging. Journal of Controlled Release 2007, 122(3):246-251.
98. Kogure K., Moriguchi R., Sasaki K., Ueno M., Futaki S., Harashima H. Development of a non-viral multifunctional envelope-type nano device by a novel lipid film hydration method. Journal of Controlled Release 2004, 98(2):317-323.
99. Komori T., Nakamura T., Matsunaga I., Morita D., Hattori Y., Kuwata H., et al. A microbial glycolipid functions as a new class of target antigen for delayed-type hypersensitivity. Jornal of Biological Chemistry 2011, 286(19):16800-16806.
100. Krawczyk M., Müllenbach R., Weber S.N., Zimmer V., Lammert F. Genome-wide association studies and genetic risk assessment of liver diseases. Nature Reviews Gastroenterology & Hepatology 2010, 7(12):669-681.
101. Kumeta M., Yamaguchi H., Yoshimura S.H., Takeyasu K. Karyopherin-independent spontaneous transport of amphiphilic proteins through the nuclear pore. Journal of Cell Science 2012, 125(Pt 21):4979-4984.
102. Kyriakouli D.S., Boesch P., Taylor R.W., Lightowlers R.N. Progress and prospects: gene therapy for mitochondrial DNA disease. Gene Therapy 2008, 15(14):1017-1023.
103. Lamm D.L., van der Meijden P.M., Morales A., Brosman S.A., Catalona W.J., Herr H.W., et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. The Journal of Urology 1992, 147(3):596-600.
104. Lanford R.E., Hildebrandt-Eriksen E.S., Petri A., Persson R., Lindow M., Munk M.E., et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010, 327(5962):198-201.
105. Lee M., Choi J.S., Choi M.J., Pak Y.K., Rhee B.D., Ko K.S. DNA delivery to the mitochondria sites using mitochondrial leader peptide conjugated polyethylenimine. Journal of Drug Targeting 2007, 15(2):115-122.
106. Lee H., Fonge H., Hoang B., Reilly R.M., Allen C. The effects of particle size and molecular targeting on the intratumoral and subcellular distribution of polymeric nanoparticles. Molecular Pharmaceutics 2010, 7(4):1195-1208.
107. Lieleg O., Baumgärtel R.M., Bausch A.R. Selective filtering of particles by the extracellular matrix: an electrostatic bandpass. Biophysical Journal 2009, 97(6):1569-1577.
108. Li L., Hoffman R.M. The feasibility of targeted selective gene therapy of the hair follicle. Nature Medicine 1995, 1(7):705-706.
109. Lindgren M., Hallbrink M., Prochiantz A., Langel U. Cell-penetrating peptides. Trends in Pharmacological Science 2000, 21(3):99-103.
110. Li W., Nicol F., Szoka F.C. GALA: a designed synthetic pH-responsive amphipathic peptide with applications in drug and gene delivery. Advanced Drug Delivery Reviews 2004, 56(7):967-985.
111. Marshall E. Gene therapy death prompts review of adenovirus vector. Science 1999, 286(5448):2244-2245.
112. Martin L.J. Mitochondriopathy in Parkinson disease and amyotrophic lateral sclerosis. Journal of Neuropathology and Experimental Neurology 2006, 65(12):1103-1110.
113. Matsuda Y., Matsumoto K., Yamada A., Ichida T., Asakura H., Komoriya Y., et al. Preventive and therapeutic effects in rats of hepatocyte growth factor infusion on liver fibrosis/cirrhosis. Hepatology 1997, 26(1):81-89.
114. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Research 1986, 46(12 Pt 1):6387-6392.
115. Mayer A., Neupert W., Lill R. Mitochondrial protein import: reversible binding of the presequence at the trans side of the outer membrane drives partial translocation and unfolding. Cell 1995, 80(1):127-137.
116. McClellan J., King M.C. Genetic heterogeneity in human disease. Cell 2010, 141(2):210-217.
117. McCormack M.P., Rabbitts T.H. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. The New England Journal of Medicine 2004, 350(9):913-922.
118. McLean J.W., Fox E.A., Baluk P., Bolton P.B., Haskell A., Pearlman R., et al. Organ-specific endothelial cell uptake of cationic liposome-DNA complexes in mice. American Journal of Physiology 1997, 273(1 Pt 2):H387-H404.
119. Mitsui M., Nishikawa M., Zang L., Ando M., Hattori K., Takahashi Y., et al. Effect of the content of unmethylated CpG dinucleotides in plasmid DNA on the sustainability of transgene expression. Journal of Gene Medicine 2009, 11(5):435-443.
120. Mold C. Effect of membrane phospholipids on activation of the alternative complement pathway. Journal of Immunology 1989, 143(5):1663-1668.
121. Moriguchi R., Kogure K., Akita H., Futaki S., Miyagishi M., Taira K., et al. A multifunctional envelope-type nano device for novel gene delivery of siRNA plasmids. International Journal of Pharmaceutics 2005, 301(1-2):277-285.
122. Morita D., Hattori Y., Nakamura T., Igarashi T., Harashima H., Sugita M. Major T cell response to a mycolyl glycolipid is mediated by CD1c molecules in rhesus macaques. Infection and Immunity 2013, 81(1):311-316.
123. Morita D., Miyamoto A., Hattori Y., Komori T., Nakamura T., Igarashi T., et al. Th1-skewed tissue responses to a mycolyl glycolipid in mycobacteria-infected rhesus macaques. Biochemical and Biophysical Research Communications 2013, 441(1):108-113.
124. Mudhakir D., Akita H., Khalil I.A., Futaki S., Harashima H. Pharmacokinetic analysis of the tissue distribution of octaarginine modified liposomes in mice. Drug Metabolism and Pharmacokinetics 2005, 20(4):275-281.
125. Mudhakir D., Harashima H. Learning from the viral journey: how to enter cells and how to overcome intracellular barriers to reach the nucleus. AAPS Journals 2009, 11(1):65-77.
126. Nakamura T., Akita H., Yamada Y., Hatakeyama H., Harashima H. A multifunctional envelope-type nanodevice for use in nanomedicine: concept and applications. Accounts of Chemical Research 2012, 45(7):1113-1121.
127. Nakamura T., Fukiage M., Higuchi M., Nakaya A., Yano I., Miyazaki J., et al. Nanoparticulation of BCG-CWS for application to bladder cancer therapy. Journal of Controlled Release 2014, 176:44-53.
128. Nakamura Y., Kogure K., Futaki S., Harashima H. Octaarginine-modified multifunctional envelope-type nano device for siRNA. Journal of Controlled Release 2007, 119(3):360-367.
129. Nakamura T., Moriguchi R., Kogure K., Harashima H. Incorporation of polyinosine-polycytidylic acid enhances cytotoxic T cell activity and antitumor effects by octaarginine-modified liposomes encapsulating antigen, but not by octaarginine-modified antigen complex. Interantional Journal of Pharmaceutics 2013, 441(1-2):476-481.
130. Nakamura T., Moriguchi R., Kogure K., Minoura A., Masuda T., Akita H., et al. Delivery of condensed DNA by liposomal non-viral gene delivery system into nucleus of dendritic cells. Biological and Pharmaceutical Bulletin 2006, 29(6):1290-1293.
131. Nakamura T., Moriguchi R., Kogure K., Shastri N., Harashima H. Efficient MHC class I presentation by controlled intracellular trafficking of antigens in octaarginine-modified liposomes. Molecular Therapy 2008, 16(8):1507-1514.
132. Naka T., Narazaki M., Hirata M., Matsumoto T., Minamoto S., Aono A., et al. Structure and function of a new STAT-induced STAT inhibitor. Nature 1997, 387(6636):924-929.
133. Netti P.A., Berk D.A., Swartz M.A., Grodzinsky A.J., Jain R.K. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Research 2000, 60(9):2497-2503.
134. Newman N.J. Leber's hereditary optic neuropathy. New genetic considerations. Archives of Neurology 1993, 50(5):540-548.
135. Nishikawa Y., Takahashi M., Yorifuji S., Nakamura Y., Ueno S., Tarui S., et al. Long-term coenzyme Q10 therapy for a mitochondrial encephalomyopathy with cytochrome c oxidase deficiency: a 31P NMR study. Neurology 1989, 39(3):399-403.
136. Nomi T., Shiota G., Isono M., Sato K., Kawasaki H. Adenovirus-mediated hepatocyte growth factor gene transfer prevents lethal liver failure in rats. Biochemical and Biophysical Research Communications 2000, 278(2):338-343.
137. Nomoto T., Matsumoto Y., Miyata K., Oba M., Fukushima S., Nishiyama N., et al. In situ quantitative monitoring of polyplexes and polyplex micelles in the blood circulation using intravital real-time confocal laser scanning microscopy. Journal of Controlled Release 2011, 151(2):104-109.
138. Ogris M., Brunner S., Schuller S., Kircheis R., Wagner E. PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene Therapy 1999, 6(4):595-605.
139. Otsuka M., Niijima K., Mizuno Y., Yoshida M., Kagawa Y., Ohta S. Marked decrease of mitochondrial DNA with multiple deletions in a patient with familial mitochondrial myopathy. Biochemical and Biophysical Research Communications 1990, 167(2):680-685.
140. Ozpolat B., Sood A.K., Lopez-Berestein G. Nanomedicine based approaches for the delivery of siRNA in cancer. Journal of Internal Medicine 2010, 267(1):44-53.
141. Pante N., Kann M. Nuclear pore complex is able to transport macromolecules with diameters of about 39 nm. Molecular Biology of the Cell 2002, 13(2):425-434.
142. Qin L., Ding Y., Pahud D.R., Chang E., Imperiale M.J., Bromberg J.S. Promoter attenuation in gene therapy: interferon-gamma and tumor necrosis factor-alpha inhibit transgene expression. Human Gene Therapy 1997, 8(17):2019-2029.
143. Quinzii C.M., Hirano M., DiMauro S. CoQ10 deficiency diseases in adults. Mitochondrion 2007, 7(Suppl.):S122-S126.
144. Raper S.E., Chirmule N., Lee F.S., Wivel N.A., Bagg A., Gao G.P., et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Molecular Genetics and Metabolism 2003, 80(1-2):148-158.
145. Redelman-Sidi G., Glickman M.S., Bochner B.H. The mechanism of action of BCG therapy for bladder cancer-a current perspective. Nature Reviews Urology 2014, 11(3):153-162.
146. Ribas A. Genetically modified dendritic cells for cancer immunotherapy. Current Gene Therapy 2005, 5(6):619-628.
147. Roos F., Terrell T.G., Godowski P.J., Chamow S.M., Schwall R.H. Reduction of alpha-naphthylisothiocyanate-induced hepatotoxicity by recombinant human hepatocyte growth factor. Endocrinology 1992, 131(6):2540-2544.
148. Sadun A.A., Chicani C.F., Ross-Cisneros F.N., Barboni P., Thoolen M., Shrader W.D., et al. Effect of EPI-743 on the clinical course of the mitochondrial disease Leber hereditary optic neuropathy. Archives of Neurology 2012, 69(3):331-338.
149. Saito N., Zhao M., Li L., Baranov E., Yang M., Ohta Y., et al. High efficiency genetic modification of hair follicles and growing hair shafts. Proceedings of the National Academy of Sciences of the United States of America 2002, 99(20):13120-13124.
150. Sakurai Y., Hatakeyama H., Akita H., Harashima H. Improvement of doxorubicin efficacy using liposomal anti-Polo-like kinase 1 siRNA in human renal cell carcinomas. Molecular Pharmaceutics 2014, 11:2713-2719.
151. Sakurai Y., Hatakeyama H., Sato Y., Akita H., Takayama K., Kobayashi S., et al. Endosomal escape and the knockdown efficiency of liposomal-siRNA by the fusogenic peptide shGALA. Biomaterials 2011, 32(24):5733-5742.
152. Sakurai Y., Hatakeyama H., Sato Y., Hyodo M., Akita H., Harashima H. Gene silencing via RNAi and siRNA quantification in tumor tissue using MEND, a liposomal siRNA delivery system. Molecular Therapy 2013, 21(6):1195-1203.
153. Saraste M. Oxidative phosphorylation at the fin de siecle. Science 1999, 283(5407):1488-1493.
154. Sarzi E., Brown M.D., Lebon S., Chretien D., Munnich A., Rotig A., et al. A novel recurrent mitochondrial DNA mutation in ND3 gene is associated with isolated complex I deficiency causing Leigh syndrome and dystonia. American Journal of Medical Genetics Part A 2007, 143(1):33-41.
155. Sato Y., Hatakeyama H., Hyodo M., Akita H., Harashima H. Development of an efficient short interference RNA (siRNA) delivery system with a new pH-sensitive cationic lipid. Yakugaku Zasshi 2012, 132(12):1355-1363.
156. Sato Y., Hatakeyama H., Sakurai Y., Hyodo M., Akita H., Harashima H. A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity invitro and invivo. Journal of Controlled Release 2012, 163(3):267-276.
157. Schapira A.H. Mitochondrial disease. Lancet 2006, 368(9529):70-82.
158. Schatz G. The protein import system of mitochondria. The Journal of Biological Chemistry 1996, 271(50):31763-31766.
159. Schroeder A., Levins C.G., Cortez C., Langer R., Anderson D.G. Lipid-based nanotherapeutics for siRNA delivery. Journal of Internal Medicine 2010, 267(1):9-21.
160. Schwarze S.R., Ho A., Vocero-Akbani A., Dowdy S.F. Invivo protein transduction: delivery of a biologically active protein into the mouse. Science 1999, 285(5433):1569-1572.
161. Schwarze S.R., Hruska K.A., Dowdy S.F. Protein transduction: unrestricted delivery into all cells?. Trends in Cell Biology 2000, 10(7):290-295.
162. Seibel P., Trappe J., Villani G., Klopstock T., Papa S., Reichmann H. Transfection of mitochondria: strategy towards a gene therapy of mitochondrial DNA diseases. Nucleic Acids Research 1995, 23(1):10-17.
163. Semple S.C., Akinc A., Chen J., Sandhu A.P., Mui B.L., Cho C.K., et al. Rational design of cationic lipids for siRNA delivery. Nature Biotechnology 2010, 28(2):172-176.
164. Shaheen S.M., Akita H., Nakamura T., Takayama S., Futaki S., Yamashita A., et al. KALA-modified multi-layered nanoparticles as gene carriers for MHC class-I mediated antigen presentation for a DNA vaccine. Biomaterials 2011, 32(26):6342-6350.
165. Shaheen S.M., Akita H., Yamashita A., Katoono R., Yui N., Biju V., et al. Quantitative analysis of condensation/decondensation status of pDNA in the nuclear sub-domains by QD-FRET. Nucleic Acids Research 2011, 39(7):e48.
166. Shanske S., Moraes C.T., Lombes A., Miranda A.F., Bonilla E., Lewis P., et al. Widespread tissue distribution of mitochondrial DNA deletions in Kearns-Sayre syndrome. Neurology 1990, 40(1):24-28.
167. Shen L., Evel-Kabler K., Strube R., Chen S.Y. Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nature Biotechnology 2004, 22(12):1546-1553.
168. Shoffner J.M., Lott M.T., Lezza A.M., Seibel P., Ballinger S.W., Wallace D.C. Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a mitochondrial DNA tRNA(Lys) mutation. Cell 1990, 61(6):931-937.
169. Sliedregt L.A., Rensen P.C., Rump E.T., van Santbrink P.J., Bijsterbosch M.K., Valentijn A.R., et al. Design and synthesis of novel amphiphilic dendritic galactosides for selective targeting of liposomes to the hepatic asialoglycoprotein receptor. Journal of Medicinal Chemistry 1999, 42(4):609-618.
170. Smirnov A., Entelis N., Martin R.P., Tarassov I. Biological significance of 5S rRNA import into human mitochondria: role of ribosomal protein MRP-L18. Genes and Development 2011, 25(12):1289-1305.
171. Snoeys J., Lievens J., Wisse E., Jacobs F., Duimel H., Collen D., et al. Species differences in transgene DNA uptake in hepatocytes after adenoviral transfer correlate with the size of endothelial fenestrae. Gene Therapy 2007, 14(7):604-612.
172. Snyder E.L., Dowdy S.F. Cell penetrating peptides in drug delivery. Pharmaceutical Research 2004, 21(3):389-393.
173. Song X.T., Evel-Kabler K., Rollins L., Aldrich M., Gao F., Huang X.F., et al. An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells. PLoS Medicine 2006, 3(1):e11.
174. Sørensen K.K., McCourt P., Berg T., Crossley C., Le Couteur D., Wake K., et al. The scavenger endothelial cell: a new player in homeostasis and immunity. American Journal of Physiology - Regulatory, Integrative and Comparative Physiology 2012, 303(12):R1217-R1230.
175. Sripada L., Tomar D., Singh R. Mitochondria: one of the destinations of miRNAs. Mitochondrion 2012, 12(6):593-599.
176. Starr R., Willson T.A., Viney E.M., Murray L.J., Rayner J.R., Jenkins B.J., et al. A family of cytokine-inducible inhibitors of signalling. Nature 1997, 387(6636):917-921.
177. Sugita M., Cernadas M., Brenner M.B. New insights into pathways for CD1-mediated antigen presentation. Current Opinion in Immunology 2004, 16(1):90-95.
178. Suzuki T., Futaki S., Niwa M., Tanaka S., Ueda K., Sugiura Y. Possible existence of common internalization mechanisms among arginine-rich peptides. The Journal of Biological Chemistry 2002, 277(4):2437-2443.
179. Suzuki Y., Kadowaki H., Atsumi Y., Hosokawa K., Katagiri H., Kadowaki T., et al. A case of diabetic amyotrophy associated with 3243 mitochondrial tRNA(leu; UUR) mutation and successful therapy with coenzyme Q10. Endocrine Journal 1995, 42(2):141-145.
180. Tabernero J., Shapiro G.I., LoRusso P.M., Cervantes A., Schwartz G.K., Weiss G.J., et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discovery 2013, 3(4):406-417.
181. Takahashi M., Yamada N., Hatakeyama H., Murata M., Sato Y., Minakawa N., et al. Invitro optimization of 2'-OMe-4'-thioribonucleoside-modified anti-microRNA oligonucleotides and its targeting delivery to mouse liver using a liposomal nanoparticle. Nucleic Acids Research 2013, 41(22):10659-10667.
182. Takara K., Hatakeyama H., Kibria G., Ohga N., Hida K., Harashima H. Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy. The Journal of Controlled Release 2012, 162(1):225-232.
183. Takehara T., Matsumoto K., Nakamura T. Cell density-dependent regulation of albumin synthesis and DNA synthesis in rat hepatocytes by hepatocyte growth factor. The Journal of Biochemistry 1992, 112(3):330-334.
184. Tanaka H., Akita H., Ishiba R., Tange K., Arai M., Kubo K., et al. Neutral biodegradable lipid-envelope-type nanoparticle using vitamin A-Scaffold for nuclear targeting of plasmid DNA. Biomaterials 2014, 35(5):1755-1761.
185. Tanaka J., Nagai T., Arai H., Inui K., Yamanouchi H., Goto Y., et al. Treatment of mitochondrial encephalomyopathy with a combination of cytochrome C and vitamins B1 and B2. Brain Development 1997, 19(4):262-267.
186. Taniike M., Fukushima H., Yanagihara I., Tsukamoto H., Tanaka J., Fujimura H., et al. Mitochondrial tRNA(Ile) mutation in fatal cardiomyopathy. Biochemical and Biophysical Research Communications 1992, 186(1):47-53.
187. Tan Y., Liu F., Li Z., Li S., Huang L. Sequential injection of cationic liposome and plasmid DNA effectively transfects the lung with minimal inflammatory toxicity. Molecular Therapy 2001, 3(5 Pt 1):673-682.
188. Taylor R.W., Chinnery P.F., Turnbull D.M., Lightowlers R.N. Selective inhibition of mutant human mitochondrial DNA replication invitro by peptide nucleic acids. Nature Genetics 1997, 15(2):212-215.
189. Thomas C.E., Ehrhardt A., Kay M.A. Progress and problems with the use of viral vectors for gene therapy. Nature Reviews Genetics 2003, 4(5):346-358.
190. Trehin R., Merkle H.P. Chances and pitfalls of cell penetrating peptides for cellular drug delivery. European Journal of Pharmaceutics and Biopharmaceutics 2004, 58(2):209-223.
191. Tuppen H.A., Blakely E.L., Turnbull D.M., Taylor R.W. Mitochondrial DNA mutations and human disease. Biochimica et Biophysica Acta 2010, 1797(2):113-128.
192. Uenishi Y., Kawabe K., Nomura T., Nakai M., Sunagawa M. Morphological study on Mycobacterium bovis BCG Tokyo 172 cell wall skeleton (SMP-105). Journal of Microbiologial Methods 2009, 77(2):139-144.
193. van der Greef J., McBurney R.N. Innovation: rescuing drug discovery: invivo systems pathology and systems pharmacology. Nature Reviews Drug Discovery 2005, 4(12):961-967.
194. van der Laan L.J., Wang Y., Tilanus H.W., Janssen H.L., Pan Q. AAV-mediated gene therapy for liver diseases: the prime candidate for clinical application?. Expert Opinion on Biological Therapy 2011, 11(3):315-327.
195. Varga C.M., Tedford N.C., Thomas M., Klibanov A.M., Griffith L.G., Lauffenburger D.A. Quantitative comparison of polyethylenimine formulations and adenoviral vectors in terms of intracellular gene delivery processes. Gene Therapy 2005, 12(13):1023-1032.
196. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Seminars in Radiation Oncology 2004, 14(3):198-206.
197. Vestweber D., Schatz G. DNA-protein conjugates can enter mitochondria via the protein import pathway. Nature 1989, 338(6211):170-172.
198. Vives E., Brodin P., Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. The Journal of Biological Chemistry 1997, 272(25):16010-16017.
199. Wallace D.C. Mitochondrial diseases in man and mouse. Science 1999, 283(5407):1482-1488.
200. Walsh C.L., Nguyen J., Tiffany M.R., Szoka F.C. Synthesis, characterization, and evaluation of ionizable lysine-based lipids for siRNA delivery. Bioconjugate Chemistry 2013, 24(1):36-43.
201. Warren A., Bertolino P., Benseler V., Fraser R., McCaughan G.W., Le Couteur D.G. Marked changes of the hepatic sinusoid in a transgenic mouse model of acute immune-mediated hepatitis. Journal of Hepatology 2007, 46(2):239-246.
202. Watanabe T., Hatakeyama H., Matsuda-Yasui C., Sato Y., Sudoh M., Takagi A., et al. Invivo therapeutic potential of Dicer-hunting siRNAs targeting infectious hepatitis C virus. Scientific Reports 2014, 4:4750.
203. Weissig V. From serendipity to mitochondria-targeted nanocarriers. Pharmaceutical Research 2011, 28(11):2657-2668.
204. Weissig V., Cheng S.M., D'Souza G.G. Mitochondrial pharmaceutics. Mitochondrion 2004, 3(4):229-244.
205. Weissig V., D'Souza G.G., Torchilin V.P. DQAsome/DNA complexes release DNA upon contact with isolated mouse liver mitochondria. The Journal of Controlled Release 2001, 75(3):401-408.
206. Wender P.A., Mitchell D.J., Pattabiraman K., Pelkey E.T., Steinman L., Rothbard J.B. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proceedings of the National Academy of Sciences of the United States of America 2000, 97(24):13003-13008.
207. Whatcott C.J., Han H., Posner R.G., Hostetter G., Von Hoff D.D. Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look. Cancer Discovery 2011, 1(4):291-296.
208. Wilson R.C., Doudna J.A. Molecular mechanisms of RNA interference. Annual Reviews of Biophysics 2013, 42:217-239.
209. Wisse E., Jacobs F., Topal B., Frederik P., De Geest B. The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer. Gene Therapy 2008, 15(17):1193-1199.
210. Wooddell C.I., Rozema D.B., Hossbach M., John M., Hamilton H.L., Chu Q., et al. Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Molecular Therapy 2013, 21(5):973-985.
211. Wyman T.B., Nicol F., Zelphati O., Scaria P.V., Plank C., Szoka F.C. Design, synthesis, and characterization of a cationic peptide that binds to nucleic acids and permeabilizes bilayers. Biochemistry 1997, 36(10):3008-3017.
212. Yamada Y., Akita H., Harashima H. Multifunctional envelope-type nano device (MEND) for organelle targeting via a stepwise membrane fusion process. Methods in Enzymology 2012, 509:301-326.
213. Yamada Y., Akita H., Kamiya H., Kogure K., Yamamoto T., Shinohara Y., et al. MITO-Porter: a liposome-based carrier system for delivery of macromolecules into mitochondria via membrane fusion. Biochimica et Biophysica Acta 2008, 1778(2):423-432.
214. Yamada Y., Furukawa R., Yasuzaki Y., Harashima H. Dual function MITO-Porter, a nano carrier integrating both efficient cytoplasmic delivery and mitochondrial macromolecule delivery. Molecular Therapy 2011, 19(8):1449-1456.
215. Yamada Y., Harashima H. Mitochondrial drug delivery systems for macromolecule and their therapeutic application to mitochondrial diseases. Advanced Drug Delivery Reviews 2008, 60(13-14):1439-1462.
216. Yamada Y., Harashima H. Delivery of bioactive molecules to the mitochondrial genome using a membrane-fusing, liposome-based carrier, DF-MITO-Porter. Biomaterials 2012, 33(5):1589-1595.
217. Yamada Y., Harashima H. Enhancement in selective mitochondrial association by direct modification of a mitochondrial targeting signal peptide on a liposomal based nanocarrier. Mitochondrion 2013, 13(5):526-532.
218. Yamada Y., Kawamura E., Harashima H. Mitochondrial-targeted DNA delivery using a DF-MITO-Porter, an innovative nano carrier with cytoplasmic and mitochondrial fusogenic envelopes. Journal of Nanoparticle Research 2012, 14(8).
219. Yan X., Kuipers F., Havekes L.M., Havinga R., Dontje B., Poelstra K., et al. The role of apolipoprotein E in the elimination of liposomes from blood by hepatocytes in the mouse. Biochemical and Biophysical Research Communications 2005, 328(1):57-62.
220. Yao S., Zhu Y., Chen L. Advances in targeting cell surface signalling molecules for immune modulation. Nature Reviews Drug Discovery 2013, 12(2):130-146.
221. Yasuzaki Y., Yamada Y., Harashima H. Mitochondrial matrix delivery using MITO-Porter, a liposome-based carrier that specifies fusion with mitochondrial membranes. Biochemical and Biophysical Research Communications 2010, 397(2):181-186.
222. Yoneda A., Couchman J.R. Regulation of cytoskeletal organization by syndecan transmembrane proteoglycans. Matrix Biology 2003, 22(1):25-33.
223. Yuan F., Dellian M., Fukumura D., Leunig M., Berk D.A., Torchilin V.P., et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Research 1995, 55(17):3752-3756.
224. Yuhki M., Yamada M., Kawano M., Iwasato T., Itohara S., Yoshida H., et al. BMPR1A signaling is necessary for hair follicle cycling and hair shaft differentiation in mice. Development 2004, 131(8):1825-1833.
225. Yu B., Hsu S.H., Zhou C., Wang X., Terp M.C., Wu Y., et al. Lipid nanoparticles for hepatic delivery of small interfering RNA. Biomaterials 2012, 33(25):5924-5934.
226. Zhang S., Zhao B., Jiang H., Wang B., Ma B. Cationic lipids and polymers mediated vectors for delivery of siRNA. The Journal of Controlled Release 2007, 123(1):1-10.
227. Zhi D., Zhang S., Cui S., Zhao Y., Wang Y., Zhao D. The headgroup evolution of cationic lipids for gene delivery. Bioconjugate Chemistry 2013, 24(4):487-519.
228. Zimmermann T.S., Lee A.C., Akinc A., Bramlage B., Bumcrot D., Fedoruk M.N., et al. RNAi-mediated gene silencing in non-human primates. Nature 2006, 441(7089):111-114.